CHD5 loss-of-function or inactivation due to promoter hypermethylation, deletions and/or mutations has been reported in breast cancer pathogenesis (Bagchi et al., 2007; Mulero-Navarro and Esteller, 2008; Wu et al., 2012). Here, CHD5 is linked to breast carcinoma.